| Literature DB >> 2454941 |
H K Webster1, A E Brown, C Chuenchitra, B Permpanich, J Pipithkul.
Abstract
The antibody response to sporozoites of Plasmodium falciparum and the role of these antibodies in protection against malaria have not been systematically investigated. An understanding of antisporozoite antibodies in natural infection is, however, important to the development of a human malaria vaccine. In a prospective study in Thailand, an antibody response to sporozoites was observed only in individuals who developed parasitemia. Antibodies were detected against an epitope in the repeat region of the circumsporozoite (CS) protein. Current candidate sporozoite vaccines are based on CS repeat antigens. The CS antibody response was of low magnitude, peaked after detection of parasitemia, and had a serum half-life of less than 1 month. CS antibody boosting occurred in only 6% of reinfected individuals. These observations suggest that antisporozoite antibody is poorly developed under natural conditions and appears not to protect against development of malaria.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2454941 PMCID： PMC266487 DOI： 10.1128/jcm.26.5.923-927.1988
Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948